Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals is conducting a Phase 3 study titled An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3). The study aims to evaluate the safety and effectiveness of linvoseltamab compared to a combination of three cancer drugs in patients with relapsed or refractory multiple myeloma, focusing on tumor shrinkage and patient survival.
The intervention being tested is linvoseltamab, an experimental drug administered through intravenous infusion. It is compared against a combination of elotuzumab, pomalidomide, and dexamethasone, which are standard treatments for multiple myeloma.
This interventional study uses a randomized, parallel assignment model without masking, focusing primarily on treatment. Participants are divided into two groups to receive either linvoseltamab or the EPd combination.
The study began on September 18, 2023, with an estimated completion date of June 23, 2025. These dates are critical for tracking the study’s progress and anticipating results that could influence treatment protocols.
The study’s progress and outcomes could significantly impact Regeneron’s stock performance and investor sentiment, especially if linvoseltamab proves to be more effective than existing treatments. This could position Regeneron favorably against competitors in the oncology market.
The study is ongoing, and further details can be found on the ClinicalTrials portal.